April W. Armstrong, MD, MPH

Panelists discuss how including adolescent patients (12 years and older) from the outset of phase 3 studies provides immediate treatment options for younger patients and increases clinician confidence in prescribing to this population.

Panelists discuss how icotrokinra demonstrated significant efficacy in high-impact areas, achieving clear or almost clear scalp in 66% of patients and clear or almost clear genital psoriasis in 77% of patients at week 16.

Discussion on differentiating spontaneous from inducible urticaria, identifying triggers, and streamlining diagnosis in dermatology and primary care.

Amanda Armstrong, MD, MPH, introduces the evolving CSU landscape and outlines key objectives: guideline alignment, treatment optimization, and integration of new targeted agents.

Panelists discuss how clinical evidence shows deucravacitinib’s superior efficacy over apremilast while underscoring the need for individualized therapy selection.

Panelists discuss how clinical evidence shows deucravacitinib’s superior efficacy over apremilast while underscoring the need for individualized therapy selection.

Panelists discuss how the durability data through week 52 show nearly 90% of adult patients and over 90% of adolescent patients maintaining PASI 75 response, addressing patient concerns about long-term treatment effectiveness.

Panelists discuss how the ICONIC-LEAD placebo-controlled studies showed icotrokinra achieving clear or almost clear skin in about 75% of patients at week 24, representing unprecedented efficacy for an oral psoriasis therapy.

Panelists discuss how deucravacitinib and apremilast act through distinct immune pathways that shape their efficacy, safety, and therapeutic roles.

Panelists discuss how oral psoriasis therapies enhance flexibility and patient-centered treatment options across varying disease severities.

Panelists discuss how the head-to-head ICONIC-ADVANCE studies demonstrated icotrokinra’s superior efficacy vs deucravacitinib, with approximately double the complete clearance rates and a safety profile similar to placebo.

Panelists discuss how icotrokinra represents a novel oral peptide that selectively blocks the IL-23 receptor, offering the trusted safety profile of IL-23 inhibition in an oral formulation with high selectivity and no off-target effects.

Panelists discuss how second-generation PDE4 inhibitors, such as orismilast, aim to improve upon apremilast’s efficacy while maintaining safety, with phase 2 data showing PASI 75 rates up to 50%.

Panelists discuss how emerging TYK2 inhibitors such as brepocitinib and ESK001 target the JAK/STAT pathway to block IL-23 and IL-17 signaling, showing promising phase 2 results with PASI 100 rates around 33% and PASI 75 rates of 64%.

Panelists discuss how effective shared decision-making involves clinicians presenting 2 to 3 optimal treatment options based on patient-specific factors rather than overwhelming patients with all possibilities or making unilateral decisions, ultimately improving treatment adherence.

Panelists discuss how many eligible patients with psoriasis remain undertreated despite advanced therapy availability due to patient discontinuation from topical burden, injection anxiety, and the historical lack of effective oral options with good safety profiles.

Panelists discuss how modern topical treatments have evolved beyond traditional corticosteroids to include more effective nonsteroidal options, such as tapinarof and roflumilast, which provide better long-term control and can complement systemic therapies.

Panelists discuss how plaque psoriasis affects 0.4% to 8% of the global population, with high-impact areas such as the scalp (up to 80% of patients) and nails (25% of patients) significantly impacting quality of life and warranting systemic therapy consideration.

An expert in dermatology provides insight on approaching treatment in patients with plaque psoriasis who have a low BSA involvement, but with symptoms that present in difficult-to-treat areas.

Dr April W. Armstrong comments on patient selection for oral systemic treatments for plaque psoriasis management.

April W. Armstrong, MD, MPH, shares her experience using oral systemic treatments in clinical practice for the management of plaque psoriasis.

An expert in dermatologic conditions examines laboratory requirements for initiating deucravacitinib in patients with moderate-to-severe plaque psoriasis and the impact of deucravacitinib on the treatment landscape.

Dr April W. Armstrong reviews key findings from the phase 3 POETYK PSO-1 and POETYK PSO-2 clinical trials evaluating the use of deucravacitinib for the treatment of plaque psoriasis.

April W. Armstrong, MD, MPH, discusses emerging therapies in oral systemics for the treatment of plaque psoriasis and shares developments in TYK2 inhibition.